Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition

Manuscript Number: 

16-0258R1

Author(s): 
Kent R. Bailey, Julie A. Fields, Carey E. Gleason, Clifford R. Jack Jr., Kejal Kantarci, Timothy G. Lesnick, Val J. Lowe, Michelle M. Mielke, Virginia M. Miller, Walter A. Rocca, Matthew L. Senjem, Lynne T. Shuster, Nirubol Tosakulwong, Samantha M. Zuk

Disclosures

Kent R. Bailey

  • Consulting Fees:
    Novartis-- CANTOS study (canakinumab in prevention of CHD) Novartis-- Pioneer-HF (drug trial on heart failure) In both cases, I'm the DSMB statistical member

Julie A. Fields

  • Nothing to Disclose

Carey E. Gleason

  • Nothing to Disclose

Clifford R. Jack Jr.

  • Consulting Fees:
    Provide consulting services for Eli Lilly

Kejal Kantarci

  • Patents/Royalties
    Data Safety Monitoring Board Takeda Inc.

Timothy G. Lesnick

  • Nothing to Disclose

Val J. Lowe

  • Consulting Fees:
    Pirimal Imaging, paid consultant; 2012-2015 Bayer Pharmaceuticals, paid consultant; 2012-2014
    Patents/Royalties
    Patent US 9,259,495, Imaging of Meningiomas Using Phenylbenzothiazole, Stilbene, or Biphenylalkyne Derivatives.
    Grants
    • Agency: 
      GE Health Care
      Dates: 
      2000-present
    • Agency: 
      AVID Radiopharmaceuticals
      Dates: 
      2008-present
    • Agency: 
      Siemens Molecular Imaging
      Dates: 
      2006-present

Michelle M. Mielke

  • Consulting Fees:
    I have consulted for Lysosomal Therapeutics, Inc. I am also on the Alzheimer Drug Discovery Scientific Review board.

Virginia M. Miller

  • Nothing to Disclose

Walter A. Rocca

  • Nothing to Disclose

Matthew L. Senjem

  • Nothing to Disclose

Lynne T. Shuster

  • Nothing to Disclose

Nirubol Tosakulwong

  • Nothing to Disclose

Samantha M. Zuk

  • Nothing to Disclose